Home Featured Page 222

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

PT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive...

MindMed Announces Financial Results for the Third Quarter 2021 and Business...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results...

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design...

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

PT273 – Erica Rex – Clinical Trials and Spontaneous Mystical Experiences

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive...

MindMed Announces Financial Results for the Third Quarter 2021 and Business...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results...

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design...

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First...

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY